Scientific Advisors
Richard C. Pasternak, MD - Chairman of the Scientific Advisory Board
See his profile under Board of Directors
Peter H. Jones, MD
Dr. Jones is Co-Director of the Lipid Metabolism and Atherosclerosis Clinic and Medical Director of the Weight Management Center at The Methodist Hospital. He is Associate Professor in the Department of Medicine, Section of Atherosclerosis and Lipid Research at the Baylor College of Medicine. Dr. Jones is a Fellow of the American College of Physicians and Fellow of the Council on Arteriosclerosis and Thromobosis of the American Heart Association. Dr. Jones' research has focused on clinical evaluation of new lipid-modifying drugs and fixed-dose lipid drug combinations. His research has also focused on the effects of weight reduction with very-low-calorie diets on plasma markers of inflammation and insulin sensitivity.
Richard H. Karas, MD, PhD
Dr. Karas is Professor and Vice Chairman of Medicine, Tufts University School of Medicine. He serves as Director of the Preventative Cardiology Center, Co-Director of the Women’s Heart Center and Associate Director of the Molecular Cardiology Research Institute. Dr. Karas' research focuses on the molecular pathways that mediate estrogen's direct effects on vascular cells. Dr. Karas also maintains an active interest in clinically-based studies focused on the regulation of vasomotor tone and on the effects of lipid lowering interventions and adverse events related to lipid-altering interventions.
Christopher P. Cannon, MD
Dr. Cannon is Senior Investigator, Thrombolysis in Myocardial Infarction (TIMI) Study Group, Associate Physician, Cardiovascular Division, Brigham and Women's Hospital, and Professor of Medicine, Harvard Medical School. In his role with TIMI, Dr. Cannon has led trials such as TACTICS-TIMI 18, PROVE IT-TIMI 22, and CALRITY-TIMI 28. Dr. Cannon has published over 500 original articles, reviews, and book chapters or electronic publications and has received numerous rewards, including the Alfred Steiner Research Award, and the Upjohn Achievement in Research Award. He serves as Chairman for several ACC and AHA committees and is editor-in-chief of the ACC's website, Cardiosource, as well as the journal Critical Pathways in Cardiology.
Eliot J. Brinton, MD FAHA, FNLA
Dr. Brinton is Director of the Metabolism Section of Cardiovascular Genetics and Associate Professor at the University of Utah School of Medicine in Salt Lake City, where he is also the Director of the LDL Apheresis Center. He is also the Immediate-Past President of the Pacific Lipid Association and President of the Utah Atherosclerosis Society, and he is a founding board member of both the National Lipid Association and of the American Board of Clinical Lipidology. Dr. Brinton’s areas of special clinical expertise include dyslipidemia and atheroprevention, diabetes mellitus and insulin resistance, obesity, estrogen replacement, and erectile dysfunction. His primary research focus is on mechanisms of human HDL metabolism in vivo and in vitro, including the effects of diet, exercise, estrogen, and insulin resistance.
David Orloff, MD
Dr. Orloff is the Medical Director at Medpace, Inc., a contract research organization based in Cincinnati, Ohio, with a focus in the metabolism/diabetes/cardiovascular disease area. From 2000-2006, he was the Director of the Division of Metabolism and Endocrinology Products at the U.S. Food and Drug Administration (FDA) where he was in charge of FDA’s regulatory oversight of new drugs for the treatment of dyslipidemia, diabetes, obesity, osteoporosis, thyroid disease, growth disorders, and inborn errors of metabolism, in addition to the panoply of other indications in endocrinology and metabolic disease. Dr. Orloff’s clinical work at NIH over the past many years has been in dyslipidemia and cardiovascular disease prevention. He was a consultant to the National Cholesterol Education Program’s Adult Treatment Panel III.